Caterpillar Inc vs Zimmer Biomet Holdings Inc — how do they compare? Caterpillar Inc trades at $856.45 (market cap $387.68B), while Zimmer Biomet Holdings Inc trades at $97.27 (market cap $18.55B). The key difference: Caterpillar Inc is far larger — about 20.9× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| CAT | ZBH | |
|---|---|---|
Market Cap | $387.68B | $18.55B |
Sector | Industrials | Health |
52-Week High | $1.06K | $107.71 |
52-Week Low | $407.79 | $79.58 |
Enterprise Value | $426.11B | $25.61B |
Dividend Yield | 0.77% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Caterpillar (CAT) trades at $837.58, down 0.55% on the day, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q2 2026 EPS of $8.17 surpassing the $6.22 expectation. Revenue growth is supported by AI data center demand, contributing to a robust $67.59B in 2025 revenue. The stock is near key support at $831, with resistance at $850.
Outlook remains positive due to strong earnings momentum and AI-driven infrastructure demand, though elevated valuation ratios (P/E of 36.32) pose a risk. Analyst consensus is bullish with a $1,010 price target, but investors should monitor macroeconomic pressures and competitive threats. The dividend history and cash flow stability add defensive appeal.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →